Odyssean LLC Purchases 17,952 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Odyssean LLC raised its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 149.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 29,924 shares of the company’s stock after acquiring an additional 17,952 shares during the period. Mirum Pharmaceuticals comprises 0.6% of Odyssean LLC’s portfolio, making the stock its 8th biggest position. Odyssean LLC’s holdings in Mirum Pharmaceuticals were worth $3,503,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Nan Fung Trinity HK Ltd. boosted its holdings in Mirum Pharmaceuticals by 45.6% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after purchasing an additional 71,214 shares during the last quarter. BlackRock Inc. acquired a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at $513,945,000. Emerald Advisers LLC increased its stake in Mirum Pharmaceuticals by 8.2% in the 1st quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock valued at $36,699,000 after buying an additional 30,129 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $1,283,000. Finally, Hillsdale Investment Management Inc. acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth about $3,762,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a research report on Monday, June 15th. Morgan Stanley set a $137.00 price target on Mirum Pharmaceuticals in a research note on Thursday, August 6th. JPMorgan Chase & Co. boosted their price target on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Finally, HC Wainwright dropped their price objective on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $137.31.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $100.90 on Friday. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The business’s 50 day moving average price is $109.09 and its two-hundred day moving average price is $101.73. The company has a market cap of $6.55 billion, a PE ratio of -6.93 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. On average, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 658 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares in the company, valued at $61,600. The trade was a 51.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at $3,631,864.50. The trade was a 14.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 133,814 shares of company stock valued at $13,914,562 in the last quarter. 8.32% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.